Literature DB >> 7865498

Acute treatment with antidepressant drugs selectively increases the expression of c-fos in the rat brain.

C H Beck1.   

Abstract

Rats were treated acutely, ip, with saline vehicle or an antidepressant: iprindole (15 mg/kg), nortriptyline (15 mg/kg), A75200 (10 mg/kg), fluoxetine (15 mg/kg), desipramine (10 mg/kg), bupropion (20 mg/kg) or tranylcypromine (7.5 mg/kg). Mapping the neuroanatomical distribution at 64 sites of the immediate early gene, c-fos revealed several patterns: first, increased counts of Fos-like neurons were found in all but one instance; second, drugs which had dopaminergic effects (bupropion and tranylcypromine) were more likely to potentiate c-fos reactivity than were the other drugs; third, Fos-like counts were more likely to be significantly elevated in structures bordering brain ventricles; fourth, only in the central amygdala were the Fos-like counts higher in all seven drug groups relative to the saline group. It remains to be seen whether or not this shared substrate is therapeutically significant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7865498      PMCID: PMC1188655     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  30 in total

1.  Effects of tricyclic antidepressants on the content and metabolism of dopamine in the rat striatum.

Authors:  P K Ghosh; P D Hrdina
Journal:  Can J Physiol Pharmacol       Date:  1977-06       Impact factor: 2.273

2.  Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy.

Authors:  E D Hendley; S H Snyder
Journal:  Nature       Date:  1968-12-28       Impact factor: 49.962

3.  Regional aspects of the prevention of learned helplessness by desipramine.

Authors:  F Petty; A D Sherman
Journal:  Life Sci       Date:  1980-04-28       Impact factor: 5.037

4.  Autoradiographic localization of [3H]-imipramine binding sites: association with serotonergic neurons.

Authors:  T M Dawson; J K Wamsley
Journal:  Brain Res Bull       Date:  1983-09       Impact factor: 4.077

5.  Desipramine (DMI): effect on the levels of acetylcholine (ACH) in whole brain and in striatum of rats.

Authors:  P D Hrdina; G M Ling; A Maneckjee
Journal:  Eur J Pharmacol       Date:  1971-06       Impact factor: 4.432

6.  The in vivo binding of [3H]-desipramine and [3H]-chlorpromazine to areas in the rat brain.

Authors:  Z Yavin; A Biegon; M Segal; D Samuel
Journal:  Eur J Pharmacol       Date:  1978-09-15       Impact factor: 4.432

7.  Relationship between plasma level and therapeutic effect of nortriptyline.

Authors:  M Asberg; B Crönholm; F Sjöqvist; D Tuck
Journal:  Br Med J       Date:  1971-08-07

8.  Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja.

Authors:  G A MacGibbon; P A Lawlor; R Bravo; M Dragunow
Journal:  Brain Res Mol Brain Res       Date:  1994-04

9.  The effects of fenfluramine and fluoxetine on the acquisition of the conditioned avoidance response in rats.

Authors:  J F McElroy; A F Du Pont; R S Feldman
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

10.  Novel antidepressants and the biogenic amine hypothesis of depression. The case for iprindole and mianserin.

Authors:  A P Zis; F K Goodwin
Journal:  Arch Gen Psychiatry       Date:  1979-09
View more
  23 in total

1.  Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs.

Authors:  B E H Sumner; L A Cruise; D A Slattery; D R Hill; M Shahid; B Henry
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

2.  Effects of antidepressant drug imipramine on gene expression in rat prefrontal cortex.

Authors:  Juha E A Knuuttila; Petri Törönen; Eero Castrén
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

3.  Comparison of ΔFosB immunoreactivity induced by vagal nerve stimulation with that caused by pharmacologically diverse antidepressants.

Authors:  Havan Furmaga; Mohona Sadhu; Alan Frazer
Journal:  J Pharmacol Exp Ther       Date:  2012-01-27       Impact factor: 4.030

4.  Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter.

Authors:  Brent J Thompson; Tammy Jessen; L K Henry; Julie R Field; Karen L Gamble; Paul J Gresch; Ana M Carneiro; Rebecca E Horton; Peter J Chisnell; Yekaterina Belova; Douglas G McMahon; Lynette C Daws; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 5.  Neuroplasticity and major depression, the role of modern antidepressant drugs.

Authors:  Gianluca Serafini
Journal:  World J Psychiatry       Date:  2012-06-22

6.  Neuroanatomical targets of reboxetine and bupropion as revealed by pharmacological magnetic resonance imaging.

Authors:  Sakthivel Sekar; J Van Audekerke; G Vanhoutte; A S Lowe; A M Blamire; A Van der Linden; T Steckler; M Shoaib; Marleen Verhoye
Journal:  Psychopharmacology (Berl)       Date:  2011-05-07       Impact factor: 4.530

7.  Androgenic influence on serotonergic activation of the HPA stress axis.

Authors:  Nirupa Goel; Kimberly S Plyler; Derek Daniels; Tracy L Bale
Journal:  Endocrinology       Date:  2011-03-08       Impact factor: 4.736

8.  Effect of antidepressant drugs on the vmPFC-limbic circuitry.

Authors:  Celene H Chang; Michael C Chen; Jun Lu
Journal:  Neuropharmacology       Date:  2015-01-28       Impact factor: 5.250

9.  Acute Impact of Selected Pyridoindole Derivatives on Fos Expression in Different Structures of the Rat Brain.

Authors:  Romana Koprdova; Jana Osacka; Mojmir Mach; Alexander Kiss
Journal:  Cell Mol Neurobiol       Date:  2017-07-10       Impact factor: 5.046

10.  Nerve growth factor (NGF) has novel antidepressant-like properties in rats.

Authors:  David H Overstreet; Kellie Fredericks; Darin Knapp; George Breese; John McMichael
Journal:  Pharmacol Biochem Behav       Date:  2009-11-27       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.